Homozygous Familial Hypercholesterolemia clinical trials

Explore recruiting homozygous familial hypercholesterolemia clinical trials.

Recruiting homozygous familial hypercholesterolemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Homozygous Familial Hypercholesterolemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Two part (double-blind inclisiran versus placebo [Year 1] followed by open-label inclisiran [Year 2]) randomized multicenter study to evaluate safety, tolerability and efficacy of inclisiran in children (2 to less than 12 years) with homozygous familial hypercholesterolemia and elevated LDL-cholesterol (ORION-19)

Spain, Greece, Germany, Netherlands, France, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 3 Single-Arm Open-Label Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent Subjects (age 12 to <18 years) with Homozygous Familial Hypercholesterolemia (SPRUCE)

Netherlands, Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 3 Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent and Adult Subjects with Homozygous Familial Hypercholesterolemia (YOSEMITE)

Greece, France, Belgium, Germany, Netherlands, Austria +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open-label, single arm, multicenter extension study to evaluate long-term safety and tolerability of inclisiran in participants with heterozygous or homozygous familial hypercholesterolemia who have completed the adolescent ORION-16 or ORION-13 studies (VICTORION-PEDS-OLE)

Germany, Spain, Hungary, Norway, Netherlands, Poland +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Open-Label Extension Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Homozygous and Heterozygous Familial Hypercholesterolemia, Cardiovascular Disease, or at High Risk for Cardiovascular Disease, on Stable Lipid-Lowering Therapy Requiring Additional Low-Density Lipoprotein Cholesterol Reduction (LIBerate-OLE)

Spain, Germany, France, Norway

Therapeutic confirmatory (Phase III) EU CTIS Study details

Homozygous Familial Hypercholesterolemia trials by city

Homozygous Familial Hypercholesterolemia in Toronto Homozygous Familial Hypercholesterolemia in Vancouver Homozygous Familial Hypercholesterolemia in Montreal Homozygous Familial Hypercholesterolemia in Calgary Homozygous Familial Hypercholesterolemia in Edmonton Homozygous Familial Hypercholesterolemia in Ottawa Homozygous Familial Hypercholesterolemia in Winnipeg Homozygous Familial Hypercholesterolemia in Quebec City Homozygous Familial Hypercholesterolemia in Hamilton Homozygous Familial Hypercholesterolemia in Kitchener Homozygous Familial Hypercholesterolemia in London Homozygous Familial Hypercholesterolemia in Halifax Homozygous Familial Hypercholesterolemia in New York Homozygous Familial Hypercholesterolemia in Los Angeles Homozygous Familial Hypercholesterolemia in Chicago Homozygous Familial Hypercholesterolemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease